Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-08-19

Clinical Trial Update: Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating 851B Gel for high-risk cervical human papillomavirus infection in women has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • 851B Gel

Snippet

Sponsor: Takeda | Conditions: Papillomavirus Infections | Phase 2 | Status: TERMINATED